Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medical backgrounder: psoriasis.

Lisa Travis1, Jeffrey M Weinberg

  • 1Department of Dermatology, St. Luke's-Roosevelt and Beth Israel Medical Centers, New York, NY, U.S.A.

Drugs of Today (Barcelona, Spain : 1998)
|February 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forensic dermatology and the crime scene investigation (CSI) effect: Are jurors influenced by forensic dermatologic investigations that they view on television, printed media, and the internet?

Clinics in dermatology·2026
Same author

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.

JAMA dermatology·2025
Same author

Predatory Conferences and Journals in Dermatology Are Black Widow Parties.

Skinmed·2024
Same author

Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2024
Same author

The impact of parental involvement laws on minors seeking abortion services: a systematic review.

Health affairs scholar·2024
Same author

Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.

Journal of the American Academy of Dermatology·2024
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Psoriasis is a chronic skin condition characterized by rapid skin cell growth, leading to characteristic lesions. Diagnosis is typically clinical, with various treatments available for moderate to severe cases.

Area of Science:

  • Dermatology
  • Immunology

Background:

  • Psoriasis is a chronic skin disorder affecting 2% of US and European populations.
  • Characterized by hyperproliferation of keratinocytes and shortened epidermal cell cycle.
  • Lesions are classified as erythrosquamous due to erythema and epidermal scale formation.

Purpose of the Study:

  • To provide an overview of psoriasis, including its characteristics, diagnosis, and therapeutic options.

Main Methods:

  • Diagnosis is primarily clinical, supported by histopathological examination when necessary.
  • Treatment strategies range from topical agents and phototherapy (UVB) to systemic agents and novel biologic therapies.

Main Results:

  • Psoriatic lesions exhibit characteristic features allowing for simple diagnosis.

Related Experiment Videos

  • Multiple therapeutic options exist, with treatment regimens including combination, rotational, and sequential therapy.

    • Conclusions:

    • Psoriasis is a common chronic skin disorder with characteristic lesions and hyperproliferation of keratinocytes.
    • Effective management involves a range of therapeutic options tailored to disease severity.